Get startedLog in
    Picture of Verona Pharma logo

    VRNA — Verona Pharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: Verona Pharma Announces US FDA Accepted NDA Filing For Ensifentrine For Maintenance Treatment Of COPD

    Picture of Verona Pharma logoVerona Pharma
    02/11/2023 07:33
    Nov 2 (Reuters) - Verona Pharma PLC  I9SAy.F :
    * VERONA PHARMA REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
AND
PROVIDES CORPORATE UPDATE
    * VERONA PHARMA PLC - US FDA ACCEPTED NDA FILING FOR
ENSIFENTRINE
FOR MAINTENANCE TREATMENT OF COPD
    * VERONA PHARMA PLC - PDUFA TARGET ACTION DATE OF JUNE 26,
2024
    * VERONA PHARMA PLC - CASH AND CASH EQUIVALENTS AT SEPTEMBER
30,
2023, WERE $257.4 MILLION
    * VERONA PHARMA PLC - QTRLY LOSS PER SHARE $0.02

Source text for Eikon:  ID:nGNX4NHcgt 
Further company coverage:  I9SAy.F

    Recent news on Verona Pharma

    See all news